LncRNA-NEAT1 inhibits the occurrence and development of pancreatic cancer through spongy miR-146b-5p/traf6

ABSTRACT

To investigate the inhibitory effect of LNCNA-NEA1 on pancreatic cancer development and progression via spongiosa miR-146b-5p/TRAF6, 60 pancreatic cancer patients diagnosed from December 2017 to December 2019 were selected as a general source of information. Real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) was used to detect the expression level of NEAT1 in cancerous and adjacent non-cancerous tissues. Cell counting kit-8 (CCK-8) and transwell were used to determine the effect of LNCNA-NEA1 on the proliferation and migration of pancreatic cancer cells (Panc-1). The results of dual luciferase reporter gene assay showed that nea 1 could target and regulate the expression of spongy miR-146b-5p/TRAF6, and reducing the expression of spongy miR-146b-5p/TRAF6 could reverse the inhibitory effects of nea 1-siRNA on proliferation, migration and invasion of pancreatic cancer cells. Therefore, it was concluded that knockdown of nea 1 could inhibit the proliferation, migration and invasion of pancreatic cancer cells by upregulating the level of miR-146b-5p/TRAF6, and the expression of lnc RNA-nea 1 could be used as an indicator for preoperative diagnosis and postoperative prognosis of pancreatic cancer patients.      

KEYWORDS:

• LncRNA-NEAT1
• MiR-146b-5p
• TRAF6
• pancreatic cancer

Acknowledgements

The authors acknowledge the XXX and XXX.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Notes on contributors

Feifei Wei

Feifei Wei is a Dr. of the Department of Oncology. Using the information technology and meta-analysis, She has invested a lot of research work in the diagnosis and treatment of various cancers. Furthermore, In view of the current progress in the treatment of pancreatic cancer, she has put more energy into this direction, and has made many meaningful discoveries

Zhiying Yan

Zhiying Yan is a Dr. of the Department of Oncology. Her main research topic is the microenvironment of pancreatic cancer and its related molecular pathways. Focusing on basic experiments, she has done a lot of research on biological behaviors such as proliferation, migration and invasion of pancreatic cancer, and made a lot of progress

Xianming Zhang

Xianming Zhang is a Dr. of the Department of Oncology. Based on his rich clinical work, he has demonstrated great ability in clinical research progress and case excavation of pancreatic cancer. On this basis, a lot of research has been carried out on the occurrence, development and prognostic factors of pancreatic cancer

Yaoyao Wang

Yaoyao Wang is a Dr. of the Department of Oncology. Her area of interest includes the application of drugs in comprehensive treatment of pancreatic cancer. She is currently researching on exploration of factors and signal pathways in the occurrence and development of pancreatic cancer

MiaoJing Wang

Jingmiao Wang is a Dr. of the Department of Oncology. She mastered many laboratory research methods skillfully, and thus made many important discoveries in the progress of pancreatic cancer. Her research direction is applying molecular research to the clinical treatment of pancreatic cancer

Yingwei Zhu

Yingwei Zhu is a Dr. of the Department of Oncology, she has presided over projects and topics of the National Natural Fund of China, and published many papers of clinical significance. Her main research field is molecular signal transduction and related clinical applications of pancreatic cancer

Kequn Xu

Kequn Xu is a Ph.D. scholar of Oncology. He is an associate professor at Changzhou Clinical Medical College of Nanjing Medical University. He is engaged in the clinical work of the cancer center of Changzhou No.2 People's Hospital, and his main research direction is the molecular mechanism, comprehensive diagnosis and treatment of pancreatic cancer